The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

What Was Tested

This observational study looks at Melanotan I and Alpha-MSH.

To investigate the effects of afamelanotide treatment on vitamin D levels in EPP.

Why It Was Studied

Patients with erythropoietic protoporphyria experience lifelong painful photosensitivity resulting in a lack of sunlight exposure.

So far, studies on vitamin D levels in EPP have only investigated patients who have not been treated with afamelanotide.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

A multicentre observational cohort study in adults with EPP from the Erasmus Medical Centre, the Netherlands, and the University Hospital Düsseldorf, Germany, was carried out.

Patient exposure to cholecalciferol or afamelanotide was categorized into four treatment groups: untreated, cholecalciferol, afamelanotide and combined treatment.

How the Study Was Run

The design is described as multicenter.

More than one site took part, so the participants came from several places.

Routinely collected vitamin D levels between 2005 and 2021 were used for analysis.

A linear mixed model for longitudinal data was applied to measure the effect of the treatment groups compared with the untreated groups on vitamin D levels.

What Was Measured

So far, studies on vitamin D levels in EPP have only investigated patients who have not been treated with afamelanotide.

PubMed files the paper under topics including Vitamin D Deficiency, Cholecalciferol, Protoporphyria, Erythropoietic, Vitamin D and alpha-MSH.

What This Means in Plain Language

The paper is a multicenter study of Melanotan I and Alpha-MSH.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (The British journal of dermatology), a journal based in England.

More context: the Melanotan I compound page and the Alpha-MSH compound page, all human trials.